PLEASE JOIN US FOR AN EDUCATIONAL WEBCAST

Real world management of haemophilia with Idelvion® and Afstyla®

Registered but not currently available in Australia and New Zealand, Idelvion (rIX-FP; albumin fusion) and Afstyla (rVIII-SingleChain) have now been used for many years in routine clinical practice across Europe and USA. Both products have become key to haemophilia management in countries where they are available.

Real world evidence studies in a number of countries have confirmed the clinical efficacy and utility of Idelvion and Afstyla. Join this **interactive webinar** to learn the latest on these studies from an international expert who prescribes these treatments on a daily basis, and to hear from a leading Australian clinician with trials experience.

DATE:

WEDNESDAY
25 SEP 2024

TIME:

6:00 PM (VIC/NSW/QLD/TAS)
5:30 PM (SA)
4:00 PM (WA)

PRESENTERS:

Prof. Johannes Oldenburg

Professor of Transfusion Medicine

Prof. Johannes Oldenburg is Director of the Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany.

He is author of over 600 publications, recipient of numerous scientific awards, journal editor & reviewer, and is active as a member of various national and international committees.

Dr. Julie Curtin

Paediatric Haematologist

Dr. Julie Curtin is a paediatric haematologist and Director of the Haemophilia Treatment Centre at The Children's Hospital, Westmead in Sydney, Australia.

She participated in clinical trials with Idelvion, making her one of the few people in Australia and New Zealand with hands-on experience of rIX-FP.

REGISTER HERE:

cslbehring.medevents.com.au

ACCESS CODE:

CSL259W

CSL Behring

PLEASE JOIN US FOR AN EDUCATIONAL WEBCAST

AGENDA (VIC/NSW/QLD/TAS):

5:30 pm	Online meeting room opens
6:00 pm	Welcome and Introduction
6:05 pm	Real world management experience
6:40 pm	ANZ insights
6:50 pm	Q&A
7:00 pm	Meeting Close

For further information, please contact:

Andrew Stork 0437 126 545 Andrew.Stork@cslbehring.com.au

Before prescribing, please review Product Information available from CSL Behring Medical Information: medicalinformation@cslbehring.com.au or call 1800 642 865

PBS Information: Afstyla &I delvion - These products are not listed on the PBS.
National Blood Authority: Afstyla & Idelvion - These products are not currently funded under the NBA arrangements.

Minimum Product Information AFSTYLA® (lonoctocog alfa), powder and solvent for solution for injection. **Indications:** In adults and paediatrics with haemophilia A for routine prophylaxis to prevent or reduce the frequency of bleeding episodes, for control and prevention of bleeding episodes, and for perioperative management (surgical prophylaxis). AFSTYLA is not indicated for the treatment of von Willebrand disease. **Contraindications:** In patients who have had lifethreatening hypersensitivity reactions to AFSTYLA, its excipients, or hamster proteins. **Precautions:** Infusion must be stopped immediately if a hypersensitivity reaction occurs. Patients should be informed of early signs of hypersensitivity. Formation of neutralising antibodies (inhibitors) to factor VIII (FVIII). Monitor using chromogenic assay or one-stage clotting assay (multiply one-stage result by 2). Use in pregnancy, lactation and previously untreated patients has not been established. **Interactions:** Interactions with other medicines have not been established. **Adverse reactions:** Reported adverse reactions include, hypersensitivity, dizziness, paraesthesia, rash, pyrexia and FVIII inhibitors. **Dosage & Administration:** Administer intravenously within 4 hours of reconstitution. Refer to Product Information for guidance on dosing on demand, for prophylaxis, in perioperative setting, and in paediatrics. Record batch number of product administered.

Minimum Product Information IDELVION® (albutrepenonacog alfa), powder and water for injection. **Indications:** In all patients with haemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes, control and prevention of bleeding episodes, and control and prevention of bleeding in the perioperative setting. **Contraindications:** Known hypersensitivity to IDELVION, its components, excipients, or hamster protein. **Precautions:** Allergic type hypersensitivity reactions possible. Immediately discontinue and initiate treatment if hypersensitivity symptoms occur. Initial administrations should be performed under medical observation. Risk of thrombotic complications. Surveillance for signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering to patients with liver disease, postoperatively, new-born infants, or to patients at risk of thrombotic phenomena or disseminated intravascular coagulation (DIC). Formation of neutralising antibodies (inhibitors) to factor IX (FIX) has been reported. Monitor patients for inhibitor development. Monitor plasma FIX activity by performing the one-stage clotting assay. **Interactions:** No interactions have been reported. **Adverse events:** Reported adverse reactions include injection site reactions, hypersensitivity, headache, dizziness, rash, eczema and FIX inhibitor development. **Dosage & Administration:** Administer intravenously after reconstitution. Monitor patient for immediate reaction. Refer to Product Information for guidance on dosing on demand, for prophylaxis, in perioperative setting, and in paediatrics. Record batch number of product administered.

By registering for this event, you agree that you are a healthcare professional registered to practice in Australia and consent to your data being collected in accordance with the CSL Behring Privacy Policy (www.csl.com/privacy-policy) and agree to receiving communications from CSL Behring in relation to this event. As CSL Behring abides by the Medicines Australia, only invitees may attend this event.

Opt-out Statement: If you do not wish to receive further information about CSL Behring services, please email customerservice@cslberhing.com.au and provide your name and contact details.

Privacy Notice: Your personal information will be used by CSL and its group legal entities (full list available here https://privacy.csl.com/csl-group-legal-entities) ('we', 'us', 'CSL') in connection with registering your attendance at this event and sending you related communications. CSL may also use your personal information to email you about products or services, as elected by you. If your personal information is not provided it may not be possible to register you for the event. We may disclose personal information to third parties including Thrivase strictly for the purpose of hosting the event, in which case we will take appropriate measures to ensure your information is maintained securely and in confidence. Some of these entities (including CSL group entities) may be located overseas. The countries in which recipients may be located include (but are not limited to) the United States, Switzerland and countries within the European Union. Further information about how CSL may use your personal information, including how you can make an enquiry or exercise any rights in relation to your personal information is set out in our Privacy Policy available at http://www.csl.com/privacy-policy.

CSL Behring (Australia) Pty Ltd ABN 66 120 398 067, Melbourne, Victoria, 3047. www.cslbehring.com.au.
Idelvion and Afstyla are registered trademarks of CSL Limited or it's affiliated companies.
Medical Information: 1800 642 865 (Australia). Date of preparation: September 2024. AU-COA-0045

This session is proudly presented by

CSL Behring